NASDAQ:IKNA Ikena Oncology - IKNA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.20 -0.06 (-1.41%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.20▼$4.4550-Day Range$2.22▼$4.4852-Week Range$1.94▼$11.79Volume1.51 million shsAverage Volume26,963 shsMarket Capitalization$152.29 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Ikena Oncology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside352.4% Upside$19.00 Price TargetShort InterestBearish8.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.02) to ($2.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.49 out of 5 starsMedical Sector841st out of 1,053 stocksBiological Products, Except Diagnostic Industry138th out of 170 stocks 3.5 Analyst's Opinion Consensus RatingIkena Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Ikena Oncology has a forecasted upside of 352.4% from its current price of $4.20.Amount of Analyst CoverageIkena Oncology has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.69% of the float of Ikena Oncology has been sold short.Short Interest Ratio / Days to CoverIkena Oncology has a short interest ratio ("days to cover") of 20.3, which indicates bearish sentiment.Change versus previous monthShort interest in Ikena Oncology has recently increased by 3.05%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIkena Oncology does not currently pay a dividend.Dividend GrowthIkena Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IKNA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Ikena Oncology this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ikena Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.81% of the stock of Ikena Oncology is held by insiders.Percentage Held by Institutions72.40% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ikena Oncology are expected to decrease in the coming year, from ($2.02) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ikena Oncology is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ikena Oncology is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIkena Oncology has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ikena Oncology (NASDAQ:IKNA) StockIkena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More Receive IKNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address IKNA Stock News HeadlinesJanuary 29, 2023 | americanbankingnews.comIkena Oncology (NASDAQ:IKNA) Trading 9.3% Higher January 15, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Achilles Therapeutics (ACHL), Novan (NOVN) and Ikena Oncology (IKNA)February 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 22, 2022 | finance.yahoo.comIs Ikena Oncology (NASDAQ:IKNA) In A Good Position To Invest In Growth?November 28, 2022 | finance.yahoo.comIkena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate UpdateNovember 22, 2022 | finance.yahoo.comIkena Oncology to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNovember 11, 2022 | finance.yahoo.comIkena Oncology Third Quarter 2022 Earnings: Beats ExpectationsNovember 10, 2022 | finance.yahoo.comIkena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial CarcinomaFebruary 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! November 7, 2022 | finanznachrichten.deIkena Oncology, Inc.: Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateNovember 7, 2022 | msn.comIkena Oncology: Q3 Earnings InsightsNovember 7, 2022 | finance.yahoo.comUPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateNovember 7, 2022 | finance.yahoo.comIkena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue EstimatesNovember 7, 2022 | finance.yahoo.comIkena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateOctober 26, 2022 | finance.yahoo.comIkena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic ResistanceOctober 18, 2022 | finance.yahoo.comIkena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo PathwayOctober 5, 2022 | finance.yahoo.comIkena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingSeptember 22, 2022 | finance.yahoo.comInvestors one-year losses grow to 71% as the stock sheds US$33m this past weekSeptember 9, 2022 | morningstar.comIkena Oncology Inc IKNA SustainabilitySeptember 6, 2022 | finance.yahoo.comIkena Oncology to Participate in September 2022 Investor ConferencesAugust 16, 2022 | nasdaq.comEarnings Update: Ikena Oncology, Inc. (NASDAQ:IKNA) Just Reported And Analysts Are Trimming Their ForecastsAugust 13, 2022 | uk.investing.comIkena Oncology, Inc. Misses Q2 EPS by 8cAugust 12, 2022 | finance.yahoo.comAnalysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS NumbersAugust 11, 2022 | msn.comIkena Oncology: Q2 Earnings InsightsAugust 11, 2022 | finance.yahoo.comIkena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateAugust 11, 2022 | finance.yahoo.comIkena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue EstimatesJuly 14, 2022 | finance.yahoo.comHow Much Of Ikena Oncology, Inc. (NASDAQ:IKNA) Do Institutions Own?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IKNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address IKNA Company Calendar Last Earnings11/07/2022Today2/02/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IKNA CUSIPN/A CIK1835579 Webikenaoncology.com Phone857-273-8343FaxN/AEmployees67Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$22.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+352.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,120,000.00 Net MarginsN/A Pretax Margin-172.89% Return on Equity-28.27% Return on Assets-23.65% Debt Debt-to-Equity RatioN/A Current Ratio7.11 Quick Ratio7.11 Sales & Book Value Annual Sales$30.99 million Price / Sales4.91 Cash FlowN/A Price / Cash FlowN/A Book Value$5.78 per share Price / Book0.73Miscellaneous Outstanding Shares36,260,000Free Float34,513,000Market Cap$152.29 million OptionableNot Optionable Beta0.80 Key ExecutivesDr. Mark Manfredi Ph.D. (Age 51)Pres. CEO & Director Comp: $795kDr. Sergio L. Santillana M.B.A. (Age 59)M.D., M.Sc., MSc, Chief Medical Officer Comp: $616kDr. Jotin Marango M.D. (Age 43)Ph.D., CFO & Head of Corp. Devel. Dr. Michelle Zhang Ph.D.Chief Scientific OfficerMs. Samantha VuksanicHead of HRMr. Jeffrey Ecsedy Ph.D. (Age 52)Chief Devel. Officer Mr. Alfredo Castro Ph.D.Exec. VP of DiscoveryMr. Alexander Constan Ph.D.Sr. VP of Non Clinical Safety & DMPKMs. Jennifer SchroederSr. VP of Clinical Devel. OperationsMr. Evan A. Hecker Ph.D.Sr. VP & Head of CMCMore ExecutivesKey CompetitorsBioAtlaNASDAQ:BCABINmune BioNASDAQ:INMBAthira PharmaNASDAQ:ATHAVaxartNASDAQ:VXRTFusion PharmaceuticalsNASDAQ:FUSNView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 32,078 shares on 11/15/2022Ownership: 5.953%Vanguard Group Inc.Bought 304,898 shares on 11/15/2022Ownership: 2.700%BlackRock Inc.Bought 214,404 shares on 11/15/2022Ownership: 1.385%State Street CorpSold 12,703 shares on 11/15/2022Ownership: 0.087%Ergoteles LLCSold 15,401 shares on 11/14/2022Ownership: 0.278%View All Institutional Transactions IKNA Stock - Frequently Asked Questions Should I buy or sell Ikena Oncology stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ikena Oncology in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IKNA shares. View IKNA analyst ratings or view top-rated stocks. What is Ikena Oncology's stock price forecast for 2023? 2 brokerages have issued 1 year price objectives for Ikena Oncology's stock. Their IKNA share price forecasts range from $16.00 to $22.00. On average, they expect the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 352.4% from the stock's current price. View analysts price targets for IKNA or view top-rated stocks among Wall Street analysts. How have IKNA shares performed in 2023? Ikena Oncology's stock was trading at $2.66 on January 1st, 2023. Since then, IKNA stock has increased by 57.9% and is now trading at $4.20. View the best growth stocks for 2023 here. When is Ikena Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our IKNA earnings forecast. How were Ikena Oncology's earnings last quarter? Ikena Oncology, Inc. (NASDAQ:IKNA) released its earnings results on Monday, November, 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.02. The firm earned $6.40 million during the quarter, compared to analyst estimates of $3.83 million. When did Ikena Oncology IPO? (IKNA) raised $125 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO. What is Ikena Oncology's stock symbol? Ikena Oncology trades on the NASDAQ under the ticker symbol "IKNA." How do I buy shares of Ikena Oncology? Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ikena Oncology's stock price today? One share of IKNA stock can currently be purchased for approximately $4.20. How much money does Ikena Oncology make? Ikena Oncology (NASDAQ:IKNA) has a market capitalization of $152.29 million and generates $30.99 million in revenue each year. The company earns $-34,120,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. How can I contact Ikena Oncology? Ikena Oncology's mailing address is 645 SUMMER STREET SUITE 101, BOSTON MA, 02210. The official website for the company is ikenaoncology.com. The company can be reached via phone at 857-273-8343 or via email at info@ikenaoncology.com. This page (NASDAQ:IKNA) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.